XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
 Psychiatry
 Genetics
 Surgery
 Aging
 Ophthalmology
 Gynaecology
 Neurosciences
 Pharmacology
 Cardiology
 Obstetrics
 Infectious Diseases
  AIDS
  Influenza
  MRSA
  Tuberculosis
  Shigella
  HCV
  SARS
  Ebola
  Dengue
  Malaria
  Pertussis
  Mumps
  Prion Diseases
  Small Pox
  Anthrax
  Leishmaniasis
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
Search

Last Updated: Nov 17th, 2006 - 22:35:04

Anthrax Channel
subscribe to Anthrax newsletter

Latest Research : Infectious Diseases : Anthrax

   DISCUSS   |   EMAIL   |   PRINT
DNI - Newly Identified Inhibitor of Anthrax Toxin May Contribute to Postexposure Therapy
Jun 20, 2005, 16:08, Reviewed by: Dr.

"The strong immunogenicity and retained antigenicity of DNI suggest that DNI is a promising and potentially safer candidate for use in an anthrax vaccine than PA," say the researchers. "Moreover, in the event of anthrax infection, the administration of DNI can serve not only as an antitoxic therapy as an immediate response but also as a prophylactic vaccine to prevent late-onset or future anthrax infection."

 
A newly identified inhibitor of the anthrax toxin may be used to develop a safer and more effective vaccine and act as a therapeutic agent after exposure say researchers from Massachusetts and Germany. Their findings appear in the June 2005 issue of the journal Infection and Immunity.

Anthrax is a highly contagious and toxic disease that results from infection with the bacterium Bacillus anthracis. If not caught immediately, those infected may die within a matter of days. Anthrax poses a deadly threat as a potential biological weapon placing added emphasis on the need for a safe and effective vaccine. The vaccine currently available doesn't protect against the bacilli and may be hazardous to its host when used immediately after exposure.

In the study researchers infected two groups of mice with anthrax and immunized one group with a dominant-negative inhibitor (DNI) and the other with a protective antigen (PA) currently used in the anthrax vaccine. They monitored the mice for several weeks and found that DNI alone produced higher immune responses than PA. Due to DNI's ability to inhibit the anthrax toxin, researchers also believe that DNI-based vaccines may increase immunity and provide therapeutic activity when administered postexposure.

"The strong immunogenicity and retained antigenicity of DNI suggest that DNI is a promising and potentially safer candidate for use in an anthrax vaccine than PA," say the researchers. "Moreover, in the event of anthrax infection, the administration of DNI can serve not only as an antitoxic therapy as an immediate response but also as a prophylactic vaccine to prevent late-onset or future anthrax infection."
 

- B.A. Aulinger, M.H. Roehrl, J.J. Mekalanos, R.J. Collier, J.Y. Wang. 2005. Combining anthrax vaccine and therapy: a dominant-negative inhibitor of anthrax toxin is also a potent and safe immunogen for vaccines. Infection and Immunity, 73. 6: 3408-3414
 

www.asm.org

 
Subscribe to Anthrax Newsletter
E-mail Address:

 

The American Academy of Microbiology is the honorific leadership group within the American Society for Microbiology (ASM), the world's oldest life science organization. The AAM is the only group of its kind devoted entirely to microbiologists and the science of microbiology.

Related Anthrax News

Monoclonal antibody recognizes a specific sugar on the surface of anthrax bacteria spores
Scientists design functionalized liposome - a potent anthrax toxin inhibitor
PlyPH protein kills anthrax bacteria by exploding their cell walls
Surprising new insights about the acid pH levels required for anthrax toxin
Diagnostic method for identifying Bacillus anthracis receives FDA approval
Protective Antigen Ion Channel Asymmetric Blockade To Detect Anthrax Infection
ABthrax(TM) Safe and Effective against Anthrax
DNI - Newly Identified Inhibitor of Anthrax Toxin May Contribute to Postexposure Therapy


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us